Same Efficacies of Ipratropium and Salbutamol in Reversing Methacholine-Induced Bronchoconstriction

References

• Crapo R O, Casaburi R, Coates A L, Enright P L, Hankinson J L, Irvin C G, MacIntyre N R, McKay R T, Wanger J S, Anderson S D, Cockcroft D W, Fish J E, Sterk P J. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med 2000; 161: 309–329, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sposato B, Mariotta S, Ricci A, Bruno P, Terzano C, Mannino F. The influence of ipratropium bromide in the recovery phase of methacholine-induced bronchospasm. Eur Rev Med Pharmacol Sci 2005; 27: 117–123, [CSA]
   Google Scholar
• Rall T W. Drugs used in the treatment of asthma. The Pharmacological Basis of Therapeutics, A Goodman Gilman, T W Rall, A S Nies, P Taylor. McGraw-Hill, New York 1992; 618–637
   Google Scholar
• Pakes G E, Brogden R N, Heel R C, Speight T M, Avery G S. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980; 20: 237–266, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Brown J H. Atropine, scopolamine and related antimuscarinic drugs. The Pharmacological Basis of Therapeutics, A Goodman Gilman, T W Rall, A S Nies, P Taylor. McGraw-Hill, New York 1992; 150–165
   Google Scholar
• Reid J K, Davis B E, Cockcroft D W. The effect of ipratropium nasal spray on bronchial methacholine challenge. Chest 2005; 128: 1245–1247, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hoffman B B, Lefkowitz R J. Catecholamines and sympathomimetic drugs. The Pharmacological Basis of Therapeutics, A Goodman Gilman, T W Rall, A S Nies, P Taylor. McGraw-Hill, New York 1992; 187–220
   Google Scholar
• Cartier A, Malo J L, Bégin P, Sestier M, Martin R R. Time course of the bronchoconstriction induced by inhaled histamine and methacholine. J Appl Physiol 1983; 54: 821–826, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gückel C, Wells A U, Taylor D A, Chabat F, Hansell D M. Mechanism of mosaic attenuation of the lungs on computed tomography in induced bronchospasm. J Appl Physiol 1999; 86: 701–708, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Beach J R, Bromly C L, Avery A J, Reid R W, Walters E H, Hendrick D J. Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol 1996; 9: 245–249, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Mannino F, Sposato B, Ricci A, Grasso D, De Clementi F, Mariotta S. Induction and recovery phases of methacholine-induced bronchoconstriction using FEV1 according to the degree of bronchial hyperresponsiveness. Lung 2001; 179: 137–145, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Quanjer P H. Standardized lung function testing. Report Working Party Standardization of Lung Function Tests, European Community for Coal and Steel. Bull Eur Physiopathol Respir 1983; 19(suppl. 5)1–95, [CSA]
   PubMedGoogle Scholar
• DuBois A B, Botelho S Y, Comroe J H. A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease. J Clin Invest 1956; 35: 327–335, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Badier M, Guillot C, Delpierre S, Fornaris E, Jacquin M. Value of bronchial challenge in scuba diving candidates. J Asthma 2000; 37: 661–665, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Orehek J, Nicoli M M, Delpierre S, Beaupré A. Influence of the previous deep inspiration on the spirometric measurement of provoked bronchoconstriction in asthma. Am Rev Respir Dis 1981; 123: 269–272, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Weiner P, Beckerman M, Berar-Yanay N, Magadle R. The perception of dyspnea after bronchoconstriction in patients with asthma. Respir Med 2003; 97: 1120–1125, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• McFadden E R, Linden D A. A reduction in maximum mid-expiratory flow rate. A spirographic manifestation of small airway disease. Am J Med 1972; 52: 725–737, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wagner E M, Liu M C, Weinmann, Permutt S, Bleecker E R. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis 1990; 141: 584–588, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Taylor P. Cholinergic agonists. The Pharmacological Basis of Therapeutics, A Goodman Gilman, T W Rall, A S Nies, P Taylor. McGraw-Hill, New York 1992; 122–130
   Google Scholar
• Wagner E M, Mitzner W A. Bronchial circulatory reversal of methacholine-induced airway constriction. J Appl Physiol 1990; 69: 1120–1224, [CSA]
   Google Scholar
• Anderson M, Svartengren M, Camner P. Human tracheobronchial deposition and effect of a cholinergic aerosol inhaled by extremely slow inhalations. Exp Lung Res 1999; 25: 335–352, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• DeSantis M, Leonetti C, Ciarpaglini L L, Pau F M, Pavone P, Pedicelli G. Reversal of air trapping as shown at expiratory high-resolution CT after drug-induced bronchodilatation: CT evaluation of pharmacologic effects in asthma (abstr). Radiology 1995; 197: 438, [CSA]
   Google Scholar
• Spina D. Airway sensory nerves: a burning issue in asthma?. Thorax 1996; 51: 335–337, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Mathieu M, Goldman M, Lellouche N, Sartene R. Kinetics of action af salbutamol inhaled from a metered dose inhaler (MDI) and a “diskhaler”. Eur J Clin Pharmacol 1992; 42: 435–438, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Beach J R, Young C L, Stenton S C, Avery A J, Walters E H, Hendrick D J. A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol 1992; 5: 133–135, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Van Noord J A, Smeets J J, Maesen F PV. A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction. Respir Med 1998; 92: 1346–1351, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Broeders M E, Molema J, Hop W C, Folgering H T. Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI. Eur J Clin Pharmacol 2005; 60: 837–841, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ruffin R E, Fitzgerald J D, Rebuck A S. A comparison of the bronchodilator activity of SCH 1000 and salbutamol. J Allergy Clin Immunol 1977; 59: 136–141, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• O'Byrne P M, Inman M D. Airway hyperresponsiveness. Chest 2003; 123: 411S–416S, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Schlueter D P. Ipratropium bromide in asthma. Am J Med 1986; 81: 55–60, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Gross N J. Sch 1000: a new anticholinergic bronchodilator. Am Rev Respir Dis 1975; 112: 823–828, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Stoodley R G, Aaron S D, Dales R E. The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a metaanalysis of randomized clinical trials. Ann Emerg Med 1999; 34: 8–18, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Melchor R, Biddiscombe M F, Mak V H, Short M D, Spiro S G. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48: 506–511, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Langley S J, Allen D, McDonnell B. The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: a randomized, placebo-controlled, double-blind, crossover study. Clin Ther 2005; 27: 1004–1012, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar